{"url":"https://lda.senate.gov/api/v1/filings/dab944d2-e370-4658-9028-2f4b7e30bcf4/","filing_uuid":"dab944d2-e370-4658-9028-2f4b7e30bcf4","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/dab944d2-e370-4658-9028-2f4b7e30bcf4/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Erika Long","dt_posted":"2020-01-21T11:15:23.507000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1962 Chatsworth way","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Tallahassee","registrant_state":"FL","registrant_zip":"32309","registrant":{"id":401105111,"url":"https://lda.senate.gov/api/v1/registrants/401105111/","house_registrant_id":null,"name":"ANWAY LONG GROUP","description":"Policy and advocacy firm","address_1":"1962 Chatsworth way","address_2":null,"address_3":null,"address_4":null,"city":"Tallahassee","state":"FL","state_display":"Florida","zip":"32309","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"EMORY ROGERS","contact_telephone":"+1 202-661-7639","dt_updated":"2022-04-06T16:08:35.271348-04:00"},"client":{"id":203210,"url":"https://lda.senate.gov/api/v1/clients/203210/","client_id":12,"name":"MALLINCKRODT LLC","general_description":"Pharmaceutical research and manufacturing","client_government_entity":false,"client_self_select":null,"state":"MO","state_display":"Missouri","country":"US","country_display":"United States of America","ppb_state":"MO","ppb_state_display":"Missouri","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-12-10"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"DEA Clearinghouse Act and other drug pricing legislation","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69757,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"LONG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"DEA Clearinghouse Act and other drug pricing legislation","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69757,"prefix":null,"prefix_display":null,"first_name":"ERIKA","nickname":null,"middle_name":null,"last_name":"LONG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}